| Schedule of segment revenues and profit |
Segment revenues, profits and reconciliation of segment profit to consolidated Income (loss) before income taxes were as follows: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended June 30, | | Salix | | International | | Solta Medical | | Diversified | | Bausch + Lomb | | Total | | (in millions) | 2026 | | 2025 | | 2026 | | 2025 | | 2026 | | 2025 | | 2026 | | 2025 | | 2026 | | 2025 | | 2026 | | 2025 | | Revenues | $ | 758 | | $ | 627 | | $ | 305 | | $ | 278 | | $ | 176 | | $ | 128 | | $ | 219 | | $ | 219 | | $ | 1,394 | | $ | 1,278 | | $ | 2,852 | | $ | 2,530 | | Less: | | | | | | | | | | | | | | | | | | | | | | | | Cost of goods sold (a) | 40 | | 39 | | 120 | | 117 | | 36 | | 36 | | 30 | | 33 | | 527 | | 523 | | | | | | Cost of other revenues | — | | — | | 19 | | 14 | | — | | — | | — | | — | | — | | 2 | | | | | | Selling, general and administrative | 100 | | 112 | | 67 | | 63 | | 40 | | 32 | | 43 | | 43 | | 476 | | 470 | | | | | | Research and development | 13 | | 21 | | 9 | | 6 | | 9 | | 6 | | 4 | | 4 | | 56 | | 35 | | | | | | Segment profit | $ | 605 | | $ | 455 | | $ | 90 | | $ | 78 | | $ | 91 | | $ | 54 | | $ | 142 | | $ | 139 | | $ | 335 | | $ | 248 | | $ | 1,263 | | $ | 974 | | Corporate | | | | | | | | | | | | | | | | | | | | | (263) | | | (261) | | | Amortization of intangible assets | | | | | | | | | | | | | | | | (225) | | | (256) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Restructuring, integration and separation costs | | | | | | | | | | | | | | | | (9) | | | (31) | | | Other expense (income), net | | | | | | | | | | | | | | | | | | | | | (26) | | | 18 | | | Operating income | | | | | | | | | | | | | | | | | | | | | 740 | | | 444 | | | Interest income | | | | | | | | | | | | | | | | | | | | | 11 | | | 13 | | | Interest expense | | | | | | | | | | | | | | | | | | | | | (396) | | | (465) | | | Gain on extinguishment of debt | | | | | | | | | | | | | | | | — | | | 178 | | | Foreign exchange and other | | | | | | | | | | | | | | | | | | | | | (7) | | | (30) | | | Income before income taxes | | | | | | | | | | | | | | | | | | $ | 348 | | | $ | 140 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Six Months Ended June 30, | | Salix | | International | | Solta Medical | | Diversified | | Bausch + Lomb | | Total | | (in millions) | 2026 | | 2025 | | 2026 | | 2025 | | 2026 | | 2025 | | 2026 | | 2025 | | 2026 | | 2025 | | 2026 | | 2025 | | Revenues: | | | | | | | | | | | | | | | | | | | | | | | | | Total revenues | $ | 1,397 | | $ | 1,169 | | $ | 590 | | $ | 540 | | $ | 347 | | $ | 241 | | $ | 404 | | $ | 424 | | $ | 2,638 | | $ | 2,415 | | $ | 5,376 | | $ | 4,789 | | Less: | | | | | | | | | | | | | | | | | | | | | | | | Cost of goods sold (a) | 87 | | 82 | | 232 | | 219 | | 89 | | 63 | | 57 | | 63 | | 1,009 | | 1,004 | | | | | | Costs of other revenues | — | | — | | 35 | | 31 | | — | | — | | — | | — | | 1 | | 3 | | | | | | Selling, general and administrative | 205 | | 223 | | 130 | | 115 | | 75 | | 60 | | 86 | | 88 | | 915 | | 917 | | | | | | Research and development | 32 | | 38 | | 15 | | 12 | | 17 | | 11 | | 7 | | 7 | | 101 | | 63 | | | | | | Segment profit | $ | 1,073 | | $ | 826 | | $ | 178 | | $ | 163 | | $ | 166 | | $ | 107 | | $ | 254 | | $ | 266 | | $ | 612 | | $ | 428 | | $ | 2,283 | | $ | 1,790 | | Corporate | | | | | | | | | | | | | | | | | | | | | (521) | | | (529) | | | Amortization of intangible assets | | | | | | | | | | | | | | | | (466) | | | (512) | | | Goodwill impairments | | | | | | | | | | | | | | | | | | | | | (1,426) | | | — | | | | | | | | | | | | | | | | | | | | | | Restructuring, integration and separation costs | | | | | | | | | | | | | | | | (22) | | | (32) | | | Other expense (income), net | | | | | | | | | | | | | | | | | | | | | (58) | | | 3 | | | Operating (loss) income | | | | | | | | | | | | | | | | | | | | | (210) | | | 720 | | | Interest income | | | | | | | | | | | | | | | | | | | | | 21 | | | 24 | | | Interest expense | | | | | | | | | | | | | | | | | | | | | (798) | | | (795) | | | (Loss) gain on extinguishment of debt | | | | | | | | | | | | | | | | (1) | | | 178 | | | Foreign exchange and other | | | | | | | | | | | | | | | | | | | | | (18) | | | (34) | | | (Loss) income before income taxes | | | | | | | | | | | | | | | | | | $ | (1,006) | | | $ | 93 | |
(a) Cost of goods sold excludes amortization and impairments of intangible assets.
|